UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q


     [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

                  For the quarterly period ended March 28, 1998



                         Commission file number 1-14019


                           SCHEIN PHARMACEUTICAL, INC.
             (Exact name of registrant as specified in its charter)


  Delaware                                                      11-2726505
--------------------------------                             -------------------
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)
                                                            

100 Campus Drive, Florham Park, NJ                                 07932
-----------------------------------------                    -------------------
(Address of principal executive offices)                        (Zip Code)


                                  973-593-5500
                  --------------------------------------------
                         (Registrant's telephone number)


       Indicate by check mark whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during the  preceeding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

Yes ...... No... X...


       The number of shares  outstanding of the registrant's  common stock as of
May 11, 1998 was 32,195,220.

<PAGE>

<TABLE>
<CAPTION>

                           SCHEIN PHARMACEUTICAL, INC.
                                      INDEX
<S>                                                                                       <C>
Part I.    FINANCIAL INFORMATION                                                          PAGE


        Item 1.   Condensed Consolidated Financial Statements

                  Condensed Consolidated Balance  Sheets as of December 27, 1997
                  and March 28, 1998.........................................................3

                  Condensed Consolidated Statements of Operations  for the three
                  months ended March 29, 1997 and March 28, 1998............................ 4

                  Condensed Consolidated  Statements of Cash Flows for the three
                  months ended March 29, 1997 and March 28, 1998............................ 5

                  Notes to Condensed Consolidated Financial Statements...................... 6

        Item 2.   Management's Discussion and Analysis of Financial Condition
                  and Results of Operation.................................................. 9


Part II.  OTHER INFORMATION

        Item 2.   Changes in Securities and Use of Proceeds.................................12

        Item 4.   Submission of Matters to a Vote of Security Holders.......................12

        Item 6.   Exhibits and Reports on Form 8-K..........................................12


SIGNATURES..................................................................................13

</TABLE>

<PAGE>


PART I. FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS

<TABLE>
<CAPTION>

                  SCHEIN PHARMACEUTICAL, INC. AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (In thousands)


                                                                              December 27,               March 28,
                                                                                  1997                      1998
                                                                           --------------------    ----------------------
                                           Assets                                                       (unaudited)
                                           ------
<S>                                                                            <C>                       <C>  
Current Assets:
   Cash and cash equivalents...............................................    $         804             $      1,203
      Accounts receivable, less allowance for possible losses of
         $2,260 and $2,145.................................................           88,781                   82,788
      Inventories..........................................................          119,142                  135,090
      Other current assets.................................................           14,035                   14,644
                                                                                ---------------          -------------
            Total Current Assets...........................................          222,762                  233,725
Property, Plant and Equipment, net.........................................          110,432                  110,087
Product Rights, Licenses and Regulatory Approvals, net.....................           86,564                   93,732
Goodwill, net                                                                         98,366                   97,283
Other Assets                                                                          16,002                   20,519
                                                                                ===============          =============
                                                                               $     534,126             $    555,346
                                                                                ===============          =============


                            Liabilities and Stockholders' Equity
                            ------------------------------------

Current Liabilities:
      Accounts payable and accrued expenses................................    $      81,478             $     82,361
      Income taxes.........................................................           11,595                   19,422
      Revolving credit and current maturities of long-term debt............           56,440                   67,800
                                                                                ---------------          -------------
            Total Current Liabilities......................................          149,513                  169,583
Long-Term Debt, less current maturities....................................          198,705                  191,435
Other Non-Current Liabilities..............................................           46,193                   45,402
Commitments and Contingencies
Stockholders' Equity:
      Common stock, $.01 par value; 100,000 authorized shares; issued and
         outstanding 28,693 shares at December 27, 1997
         and March 28, 1998................................................              287                      287
      Additional paid-in capital...........................................           38,494                   38,494
      Retained earnings....................................................           99,483                  108,605
      Accumulated other comprehensive income...............................            1,502                    1,540
       Other                                                                             (51)                      --
 ..............................................................................
                                                                                -------------------      -------------
            Total Stockholders' Equity........................................       139,715                  148,926
                                                                                -------------------      -------------
                                                                               $     534,126             $    555,346
                                                                                ===================      =============
</TABLE>

     See accompanying notes to condensed consolidated financial statements.

<PAGE>

<TABLE>
<CAPTION>

                  SCHEIN PHARMACEUTICAL, INC. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                    (In thousands, except earnings per share)
                                   (unaudited)

                                                                                                  Three Months Ended
                                                                                     ---------------------------------------------
                                                                                           March 29,                   March 28,
                                                                                              1997                        1998
                                                                                     ---------------------        ----------------
<S>                                                                                 <C>                          <C>     
Net Revenues....................................................................    $          131,839           $        146,678
Cost of Sales...................................................................                87,117                     94,793
                                                                                  ---------------------        -------------------

           Gross profit.........................................................                44,722                     51,885
Costs and Expenses:
           Selling, general and administrative..................................                19,942                     21,572
           Research and development.............................................                 6,744                      7,147
           Amortization of goodwill and other intangibles.......................                 2,550                      2,574
                                                                                  ---------------------         ------------------
 .....
Operating Income................................................................                15,486                     20,592
           Interest expense, net................................................                 6,884                      5,992
           Other expenses (income), net.........................................                 1,094                     (1,522)
                                                                                  ---------------------         ------------------

Income Before Provision for Income Taxes........................................                 7,508                     16,122
Provision for Income Taxes......................................................                 3,625                      7,000
                                                                                  ---------------------        -------------------

Net Income......................................................................    $            3,883           $          9,122
                                                                                  =====================        ===================



Basic and Diluted Earnings Per Share............................................    $             0.14           $           0.32
                                                                                  =====================        ===================

Weighted Average Common Shares and Equivalents..................................                28,755                     28,819
                                                                                  =====================        ===================

</TABLE>

     See accompanying notes to condensed consolidated financial statements.

<PAGE>

<TABLE>
<CAPTION>

                  SCHEIN PHARMACEUTICAL, INC. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (In thousands)
                                   (unaudited)

                                                                                             Three Months Ended
                                                                                    -------------------------------------
                                                                                       March 29,            March 28,
                                                                                          1997                 1998
                                                                                    -----------------     ---------------
<S>                                                                              <C>                   <C>
Cash flows from operating activities:
   Operating activities:
   Net income................................................................... $          3,883        $     9,122
     Depreciation and amortization..............................................            7,109              6,357
     Deferred income tax benefit................................................             (677)              (938)
     Gain on sale of marketable securities......................................               --             (2,796)
     Other......................................................................            1,306              1,476
   Changes in assets and liabilities:
     Accounts receivable........................................................            3,793              5,793
     Inventories................................................................           (5,583)           (15,948)
     Prepaid expenses and other assets..........................................               86               (655)
     Accounts payable, income taxes, accrued expenses
         and other liabilities..................................................            5,738              8,710
                                                                                 -----------------     --------------
Net cash provided by operating activities.......................................           15,655             11,121
                                                                                 -----------------     --------------

Cash flows from investing activities:
     Capital expenditures, net..................................................           (2,641)            (2,808)
     Product rights and licenses................................................               --             (8,766)
     Investment in Cheminor Drugs Ltd...........................................               --             (6,234)
     Proceeds from the sale of marketable securities............................               --              4,107
     Other, net.................................................................              (82)              (609)
                                                                                 -----------------     --------------

Net cash used in investing activities...........................................           (2,723)           (14,310)

Cash flows from financing activities:
     Principal payments on, or repayments of, debt..............................          (53,021)           (50,025)
     Proceeds from issuance of debt.............................................           39,000             54,115
     Increase in other non-current assets.......................................               --               (502)
                                                                                 -----------------     --------------
Net cash provided by (used in) financing activities.............................          (14,021)             3,588
                                                                                 -----------------     --------------

Net increase (decrease) in cash and cash equivalents............................           (1,089)               399
Cash and cash equivalents, beginning of period..................................            2,139                804
                                                                                 -----------------     --------------

Cash and cash equivalents, end of period........................................  $         1,050       $      1,203
                                                                                 =================     ==============

</TABLE>

     See accompanying notes to condensed consolidated financial statements.

<PAGE>

                  SCHEIN PHARMACEUTICAL, INC. AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


NOTE 1--SUMMARY OF ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information and with the  instructions to Form 10-Q and Rule 10-01 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial statements. In the opinion of management,  all adjustments (consisting
of only normal recurring accruals)  considered necessary for a fair presentation
have been included.  Operating results and cash flows for the three month period
ended March 28, 1998 are not  necessarily  indicative of the results that may be
expected for the year ending December 26, 1998. For further information refer to
the consolidated  financial statements and footnotes thereto for the 1997 fiscal
year incorporated by reference in the Company's  Registration  Statement on Form
S-1 dated April 8, 1998.

Basic earnings per share has been computed using the weighted  average number of
shares of common stock  outstanding.  Diluted  earnings per share is the same as
the basic  amounts for all  periods  presented.  The  assumed  exercise of stock
options could potentially dilute earnings per share amounts in the future.


NOTE 2--INVENTORIES

Inventories are summarized as follows:

<TABLE>
<CAPTION>
                                                              December 27,       March 28, 
                                                                  1997              1998
                                                             -------------    -------------
                                                                    (In thousands)
<S>                                                          <C>              <C>
Finished products......................................      $    45,568      $   44,474
Work-in-process........................................           33,160          44,822
Raw materials and supplies.............................           40,414          45,794
                                                             =============    =============
                                                              $  119,142       $ 135,090
                                                             =============    =============

</TABLE>

NOTE 3--STRATEGIC ALLIANCES

In February 1998, the Company entered into a strategic  alliance  agreement with
Cheminor  Drugs  Limited  and its  subsidiaries  ("Cheminor")  and  Dr.  Reddy's
Laboratories Limited and its subsidiaries ("Reddy").  Pursuant to the agreement,
Cheminor  will make  available to the Company its present and future dosage form
generic  products on an exclusive  basis in the United  States and certain other
countries, and the Company will make available to Cheminor and Reddy its present
and future  products on an exclusive  basis for sale in India and certain  other
countries.  Cheminor  and Reddy will make  available  to the Company bulk active
pharmaceutical ingredients. As part of the arrangement,  the Company purchased 2
million  shares of  Cheminor  (12.79%  of the  currently  outstanding  shares of
Cheminor)and other rights for $10 million,  of which $6.2 million represents the
fair  value of the stock  and $3.8  million  represents  product  rights.  Under
certain  circumstances  the  Company  has the right  and/or  the  obligation  to
purchase an additional 1 million  shares for $5 million.  Cheminor has the right
to make fair market value purchases of the Company's  common stock; the purchase
price may be payable from profits otherwise due Cheminor from the alliance. Each
party will also be entitled to  representation  on the other  company's board of
directors consistent with its equity interest.

<PAGE>

                  SCHEIN PHARMACEUTICAL, INC. AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)



NOTE 4--COMPREHENSIVE INCOME

Effective in fiscal 1998, the Company adopted Statement of Financial  Accounting
Standards No. 130,  "Reporting  Comprehensive  Income." This Statement  requires
that  all  items  recognized   under  accounting   standards  as  components  of
comprehensive  earnings  be reported in an annual  financial  statement  that is
displayed with the same prominence as other annual  financial  statements.  This
Statement  also requires that an entity  classify  items of other  comprehensive
earnings by their nature in an annual financial  statement.  For example,  other
comprehensive  earnings may include foreign  currency  translation  adjustments,
minimum  pension  liability  adjustments,  and  unrealized  gains and  losses on
marketable  securities  classified  as   available-for-sale.   Annual  financial
statements for prior periods will be  reclassified,  as required.  The Company's
total comprehensive earnings for the periods indicated were as follows:

<TABLE>
<CAPTION>

                                                                                      Three Months Ended
                                                                             -------------------------------------
                                                                             March 29, 1997         March 28, 1998
                                                                             --------------        ---------------
                                                                                       (In thousands)
<S>                                                                            <C>                 <C>
Net Income............................................................         $      3,883        $    9,122
                                                                               -------------       ------------

Other Comprehensive Income, net of tax:
      Foreign currency translation adjustments........................                   27               (34)
      Unrealized holding gains arising during period..................                5,028             1,736
      Less:  Reclassification adjustment for gains
                     included in net income...........................                                 (1,664)
                                                                               -------------       ------------
Other Comprehensive Income............................................                5,055                38
                                                                               -------------       ------------

Comprehensive Income..................................................         $      8,938        $    9,160
                                                                               =============       ============

</TABLE>

Components of accumulated other comprehensive income,  included in the Company's
balance sheet, are as follows:

<TABLE>
<CAPTION>

                                                                           December 27, 1997         March 28, 1998
                                                                           -----------------         ---------------
                                                                                        (In thousands)
<S>                                                                           <C>                 <C>
Unrealized gains on marketable securities...............................       $     2,286        $         2,358
Cumulative foreign currency translation adjustment                                    (784)                  (818)
                                                                                ------------       ---------------
                                                                               $     1,502        $         1,540
                                                                                ============       ===============

</TABLE>

<PAGE>

                  SCHEIN PHARMACEUTICAL, INC. AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)



NOTE 5--SUBSEQUENT EVENTS

On March 31, 1998, the Company  entered into an agreement with Elan  Corporation
plc covering  several  products in various stages of development in the areas of
oral  sustained-release  and  transdermal  products.  Under the  agreement,  the
Company is obligated to pay $14 million in  development  and license  fees,  and
additional  development  and  license  fees  based  on  achievement  of  certain
milestones.

On April 9, 1998, the Company  consummated  an initial  public  offering of 3.45
million shares of common stock which generated net proceeds of approximately $53
million.  The majority of the  proceeds of the offering  were used to retire $50
million of the  Company's  senior  floating  rate notes.  This will result in an
extraordinary  charge of approximately  $2 million,  net of taxes, for the early
extinguishment of debt in the second quarter of 1998. This extraordinary item is
for the  writeoff  of  non-cash  deferred  fees and  costs  associated  with the
reacquisition of the notes.



<PAGE>


Item 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS


Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Certain  statements in this Form 10-Q constitute  "forward  looking  statements"
within the  meaning of the  Private  Securities  Litigation  Reform Act of 1995,
including  those  concerning  management's  expectations  with respect to future
events or results.  These forward looking statements involve certain significant
risks and  uncertainties,  and actual  results  may differ  materially  from the
forward looking  statements.  Some important  factors which may cause results to
differ include:  the difficulty of predicting FDA approvals,  the uncertainty of
acceptance and demand for the Company's new products,  the impact of competitive
products  and  pricing,   the  availability  of  raw  materials,   uncertainties
associated with litigation  (including without limitation patent challenges) and
regulatory  matters,  and  fluctuations  in operating  results.  Other important
factors  that may cause  actual  results to differ  materially  from the forward
looking  statements  are  discussed  in the  "Risk  Factors"  and  "Management's
Discussion & Analysis of Financial Condition and Results of Operations" sections
of the  Company's  prospectus  dated  April 8,  1998,  which is on file with the
Securities  and  Exchange  Commission  as  part  of the  Company's  Registration
Statement on Form S-1.


Results of Operations:

Three Months Ended March 28, 1998 Compared to Three Months Ended March 29, 1997

The  following  table  sets  forth  comparisons  of  net  product  revenues  and
settlement revenues for each of the periods shown:

<TABLE>
<CAPTION>

                                                                                             Three Months Ended
                                                                                   ---------------------------------------
                                                                                      March 29,           March 28, 1998
                                                                                         1997
                                                                                   -----------------     -----------------
                                                                                               (In millions)
                                                                                                (unaudited)
<S>                                                                                  <C>                   <C>
Product revenues................................................................     $    106.8            $     116.7
Patent reviews:  settlement revenues............................................           25.0                   30.0
                                                                                   --------------        ---------------
      Total net revenues........................................................     $    131.8            $     146.7
                                                                                   ==============         ==============

</TABLE>


Net revenues  for the first three months of 1998  increased  $14.9  million,  or
11.3%,  from $131.8 million in 1997 to $146.7 million in 1998.  Product revenues
increased  $9.9 million and  settlement  revenues  increased  $5.0 million.  The
increase  in product  revenues  is  attributable  to volume  increases  of $13.7
million partially offset by price erosion of $3.8 million.  New generic products
that  contributed to increased  revenues of $14.0 million were  methylphenidate,
ketoprofen  ER (both  launched  in the fourth  quarter  of 1997) and  ranitidine
(launched  during  the later  part of the  first  quarter  of 1998).  Settlement
revenues in 1997 and 1998 reflects funds received from a pharmaceutical  company
pursuant to an agreement  reached with the company in 1994.  Under the agreement
the  Company  received a final  payment of $30  million in the first  quarter of
1998,  half of which was paid to the  Company's  consultant.  In addition to the
amounts  paid to the  consultant,  the Company  incurs  substantial  other costs
related  to  its  patent  review  activities  as  part  of its  overall  product
development activities.

Gross profit increased $7.2 million in the first quarter of 1998, or 16.0%, from
$44.7 million in 1997 to $51.9 million in 1998.  The gross margin  improved from
33.9% in the 1997 interim  period to 35.4% in the 1998  period.  The increase in
gross profit was principally the result of the volume increases and the increase
in settlement revenues, partially offset by price erosion.

Selling,  general and administrative  expenses increased $1.7 million,  or 8.2%,
from  $19.9  million  in 1997 to $21.6  million in 1998.  Selling,  general  and
administrative  expenses as a percent of net  revenues  decreased  from 15.1% in
1997 to 14.7% in 1998.  The  increase  in selling,  general  and  administrative
expenses  was due  primarily  to an  increase  in brand  selling  and  marketing
expenses.  The Company has begun expanding its brand sales and marketing efforts
to target use of INFeD(R) in the oncology  community for the treatment of cancer
patients who are anemic and iron deficient. The expansion is also in preparation
for the  launch  into the  renal  care  market of  Ferrlecit(R),  which has been
submitted to the FDA.  Ultimately,  the Company  expects to increase its branded
sales force by about 50% to a total of approximately 30 representatives.

Research and  development  expenses  increased $0.4 million,  or 6.0%, from $6.7
million in 1997 to $7.1  million in 1998,  as a result of general  increases  in
research  and  development  activities.  During the first  quarter of 1998,  the
Company and its alliance partners received seven ANDA approvals from the FDA.

Amortization of goodwill and other intangibles was unchanged from the comparable
period in 1997.

As a result of the factors  discussed  above,  operating  income  increased $5.1
million, or 33.0%, from $15.5 million in 1997 to $20.6 million in 1998.

Interest expense,  net,  decreased $0.9 million,  or 13.0%, from $6.9 million in
1997 to $6.0  million in 1998  principally  due to lower  debt  levels and lower
borrowing  rates as higher cost  subordinated  debt was exchanged for lower cost
senior floating rate notes in December 1997.

Other expenses  (income),  net,  changed by $2.6 million from an expense of $1.1
million in 1997 to income of $1.5 million in 1998 and was due primarily to gains
on the sale of marketable securities of $2.8 million.

The Company's  effective  tax rate is higher than the statutory  rate due to the
effect of significant  non-deductible  expenses,  which is largely  comprised of
amortization of intangibles. The effective tax rate decreased from 48.3% in 1997
to 43.4% in 1998,  primarily  as a result  of  higher  income  offsetting  fixed
non-deductible expenses.


Liquidity and Capital Resources

Net cash provided by operating activities was $11.1 million for the three months
ended March 1998. The net cash provided by operating  activities during 1998 was
attributable to net income as adjusted for non-cash charges of $13.2 million, an
increase in accounts  payable  and accrued  expenses  and a decrease in accounts
receivable of $14.5 million,  offset by an increase in  inventories  and prepaid
expenses and other assets of $16.6 million.

Net cash used in  investing  activities  was $14.3  million for the three months
ended March 1998. Cash used in investing  activities consisted of the investment
in Cheminor of $6.2  million,  payment for product  rights and  licenses of $8.8
million, and capital  expenditures of $2.8 million,  offset by the proceeds from
sales of marketable securities of $4.1 million.


<PAGE>


Net cash of $3.6 million  provided by financing  activities for the three months
ended March 1998 was derived  primarily from borrowings on the Company's line of
credit reduced by the long term debt.

On April 9, 1998, the Company  consummated  an initial  public  offering of 3.45
million shares of common stock which generated net proceeds of approximately $53
million.  The majority of the  proceeds of the  offering  were used to repay $50
million of the  Company's  senior  floating  rate notes.  This will result in an
extraordinary  charge in the second quarter of 1998 for the writeoff of non-cash
deferred  fees and the  costs  associated  with the  reacquisition  of the notes
amounting to approximately $2 million, net of taxes. It is anticipated that this
will save the Company  approximately  $3.3  million in interest  expense for the
remainder of the current fiscal year.

The Company  believes that cash  generated from  operations and existing  credit
facilities are sufficient to finance its current level of operations through the
next  twelve  months.  In the  event  that the  Company  makes  any  significant
acquisitions,  it may be required to obtain  additional  funds.  There can be no
assurance  that such funds,  if required,  would be available  or, if available,
would be on terms acceptable to the Company.


<PAGE>


PART II.  OTHER INFORMATION

Item 2.  CHANGES IN SECURITIES AND USE OF PROCEEDS

On April 9, 1998,  the Company  consummated  an initial  public  offering of its
common  stock,  pursuant  to  Registration  Statement  No.  333-41413  (covering
3,450,000  shares sold by the Company) filed with and declared  effective by the
Securities and Exchange  Commission on April 8, 1998. The managing  underwriters
were Cowen & Co., Bear Stearns & Co. Inc.,  and Smith Barney Inc. At the initial
offering  price of $17 per share,  the common  shares sold for an  aggregate  of
$58.6 million with  underwriters'  discount and  commissions of $4.1 million and
other costs and  expenses of  approximately  $1.5  million.  Net proceeds to the
Company, after deducting  underwriters' discount and commissions and other costs
and  expenses  of the  offering,  were  approximately  $53  million.  Of the net
proceeds to the  Company,  $50 million was used to retire a portion of Company's
senior  floating rate notes with the remainder used to reduce  borrowings  under
its revolving credit agreement.


Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On March 20, 1998, prior to the Company's  initial public  offering,  the Annual
Meeting of the  Stockholders  of the  Company  was held in Florham  Park,  NJ. A
quorum was present at the meeting and acting  throughout.  The  following  items
were  approved  by all the  shares  represented  at the  meeting,  which  were a
majority of the shares outstanding at that date:

           1.    Restatement of the Company's Certificate of Incorporation; and

           2.   Election of the following  individuals to the Board of Directors
                of the Company: Martin Sperber, Richard Goldberg (terms expiring
                in 1999), Dariush Ashrafi (term expiring in 2000), Paul Feuerman
                and David Ebsworth (terms expiring 2001).


Item 6.  EXHIBITS AND REPORTS ON FORM 8-K


           (a)     Exhibits
                   27 - Financial Data Schedule

           (b)     Reports on Form 8-K
                   None


<PAGE>


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                           Schein Pharmaceutical, Inc.
                           (Registrant)


                            By:  MARTIN SPERBER
                                 -------------------------------------------
                                 Martin Sperber
                                 Chairman of the Board,
                                 Chief Executive Officer and President
                                 (Principal Executive Officer)



                            By:  DARIUSH ASHRAFI
                                 -------------------------------------------
                                 Dariush Ashrafi
                                 Chief Financial Officer and
                                 Executive Vice President
                                 (Principal Financial and Accounting Officer)


Dated:  May 13, 1998